首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

2109019

器官晶片器官：市場洞察、競爭格局與市場預測 - 2034 年

Organ-on-Chip - Market Insights, Competitive Landscape, and Market Forecast - 2034

出版日期: 2026年08月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

概述：

預計到 2025 年，晶片器官晶片市場價值將達到 5.2 億美元，到 2034 年將達到 31 億美元。這一成長的促進因素包括：從動物試驗加速轉向與人體高度相關的微生理系統；製藥業擴大採用預測性臨床前模型；以及 FDA 和其他全球監管機構的支持。
全球器官晶片市場預計在 2026 年至 2034 年的預測期內將以 22.0% 的複合年成長率成長。
按產品類型分類，預計到 2025 年，產品細分市場（設備、耗材和配件）將佔 64% 的市場佔有率，從而推動器官晶片市場的發展。
按器官類型分類，「晶片肝臟」細分市場預計到 2025 年將佔 29% 的佔有率，從而推動器官晶片市場的發展。
按應用領域分類，預計到 2025 年，藥物發現和開發領域將佔市場佔有率的 41%，從而推動器官晶片市場的發展。
按最終用戶分類，預計到 2025 年，製藥和生物技術公司將引領器官晶片市場，佔據 57% 的市場佔有率。
到 2025 年，北美將佔全球器官器官晶片市場收入的 48%，在全球區域市場佔有率中佔據最高比例。

器官晶片（OoC）是微流體細胞培養裝置，其內壁襯有活體人類細胞，能夠在微型平台上模擬特定人體器官或器官界面的結構、力學作用和生理反應。由於這些系統結合了人源細胞、生物材料和精確控制的流體，因此與傳統的2D細胞培養或動物模型相比，它們能夠產生更多與人體相關且更具預測性的藥物療效、毒性和疾病機制數據，同時支持全球範圍內減少、最佳化和替代動物試驗的趨勢。本市場依產品類型分為設備、耗材及配件及服務。依器官類型分類，包括肝臟、肺臟、心臟、腎臟等器官，例如皮膚、腸道和多器官（晶片人體）系統。按應用領域分類，則包括藥物發現與開發、藥物毒性測試、疾病建模、個人化醫療以及藥物動力學和動態研究。此外，從最終用戶來看，製藥和生物技術公司、學術和研究機構以及受託研究機構是主要組成部分。在加速法規核准新調查方法（NAM）、製藥公司在預測毒理學領域外包業務增加以及與大型製藥企業合作不斷深化的推動下，器官晶片平台正從科學概念驗證階段發展成為現代人體藥物研發工具包中不可或缺的重要組成部分。

器官晶片器官市場的主要市場促進因素

美國食品藥物管理局 (FDA) 於 2025 年 4 月宣布了藍圖，計劃在未來三到五年內逐步取消臨床前安全性和毒性測試中的動物試驗要求，這直接加速了製藥業採用器官晶片和其他新的調查方法方法 (NAM)。
此外，美國國立衛生研究院 (NIH) 於 2025 年中期宣布的政策要求，在使用動物模型的新資助申請中必須納入以人為中心的方法，包括器官晶片，這正在擴大學術和轉化研究計畫對研究級材料的需求。
Emulate 公司的「肝臟晶片」已成為首個被 FDA 的「創新科學和技術方法新藥 (ISTAND)」計劃採用的器官晶片，該計劃有望建立監管合格評估途徑，並加速 FDA 對基於晶片的數據的更廣泛接受。
器官晶片開發公司與大型製藥公司之間的策略夥伴關係正在不斷深化，例如 Emulate 與羅氏、Astra Zeneca、默克和強生等公司的合作，以及 Hesperos 與拜耳消費者健康和 Cyrela 的合作，這些合作將基於晶片的測試確立為贊助公司藥物安全工作流程中不可或缺的一部分。
隨著心血管疾病、癌症和神經退化性疾病等慢性複雜疾病的全球負擔不斷加重，對生理有效的疾病建模和毒性測試平台的需求也在不斷成長。
隨著英國在 2025 年 11 月採取措施減少對動物試驗的依賴，以及美國以外地區監管力度的加大，預計器官晶片的應用領域正在擴大。
由 MIMETAS、TissUse、InSphero 和其他創始成員於 2025 年 2 月發起的「微生理系統產業聯盟 (IAMPS)」等行業聯盟的成立，促進了檢驗方法的標準化，並提高了買家對該技術的信心。
監管部門的批准、與大型製藥企業的合作、疾病負擔的減輕以及跨行業的標準化，都是推動市場在 2034 年之前保持強勁兩位數成長的因素。

推動晶片器官晶片市場成長的因素

市場促進因素

非動物試驗方法的法規核准正在加速進行。

器官器官晶片市場最大的驅動力是監管政策加速從動物實驗轉向新的、經過驗證的調查方法。 2025年4月，美國食品藥物管理局（FDA）宣布了一項戰略藍圖，旨在三到五年內將動物檢驗從臨床前安全性和毒性測試的“標準”轉變為“例外”，並將器官晶片技術定位為與類器官、計算模型和人工智慧並駕齊驅的核心替代工具。同年，美國國立衛生研究院（NIH）也支持這一方向，要求涉及動物模型的新資助計畫必須採用以人為中心的方法。 Emulate公司的「肝臟晶片」成為首個被FDA的ISTAND計畫認可的器官晶片技術。 ISTAND專案是一個針對不符合現有框架的工具的認證流程，它為資助公司提供了一條清晰的途徑，使其能夠以符合監管要求的方式利用從晶片獲得的數據。隨著這些框架的成熟和擴展到更多器官系統和疾病的背景下，預計製藥贊助商將在其藥物開發平臺中穩步增加器官晶片的使用，這將推動市場成長到 2034 年。

深化與大型製藥企業的策略夥伴關係

器官晶片開發公司與大型製藥公司之間的夥伴關係正以結構性浪潮的形式迅速蔓延，這項技術也逐漸成為藥物安全性和有效性評估的主流工作流程。 Emulate 已與羅氏、Astra Zeneca、默克和強生等公司建立了策略合作夥伴關係，合作領域涵蓋安全性預測、疾病機制和患者來源細胞模型。同時，Hesperos 與拜耳消費者健康公司合作開發了一種用於研究壓力誘導認知障礙的「人體晶片」模型，並與 Psilera 合作推進針對額顳葉型失智症的神經精神候選藥物的臨床前建模。 CN Bio 和 Altis Biosystems 共同開發了新一代人體腸道和肝臟體外模型，以支援先進的 ADME 研究。這些與贊助公司的緊密合作正在藥物決策領域展示器官晶片技術的應用，為平台提供者創造持續的收入，並建立永續的參考項目，從而在預測期內加速更多贊助公司採用這項技術。

市場限制因素

儘管器官器官晶片市場發展勢頭強勁，但仍面臨許多限制因素。器官晶片設備、儀器和耗材的高成本，以及操作所需的先進微流體和細胞生物學專業知識，限制了小規模學術實驗室和預算有限的研究機構的採用。除了FDA的ISTAND舉措等初期計畫外，缺乏完全統一的監管合格流程，使得希望在監管申請中使用晶片衍生數據的申辦方面臨不確定性，從而減緩了其更廣泛的應用。與實驗室間可重複性、細胞來源標準化以及臨床結果的長期檢驗相關的技術挑戰，仍然是目前積極研究的領域。來自新興替代調查方法（例如類器官、電腦和人工智慧建模以及先進的2D/3D共培養系統）的競爭，正在加劇市場碎片化，並形成快速演進的競爭格局。微流體、組織工程和轉化生物學領域專家的短缺限制了規模化生產的步伐，而許多專業供應商的低通量生產能力也限制了能夠向大型製藥企業客戶供應的晶片數量。這些成本、監管、技術和人才方面的障礙正在減緩成長速度，但法規核准、疾病負擔和製藥業的業務外包等根本促進因素仍然強勁。

器官晶片器官市場：市場促進因素
- 非動物試驗方法的監管批准
- 深化與大型製藥企業的夥伴關係和策略聯盟
- 全球慢性病和複雜疾病負擔日益加重
- 預測毒理學領域藥物外包的擴張
晶片器官晶片市場：限制因素與挑戰
- 高成本和對專業知識的需求
- 法規核准和標準化的差距
- 可重複性、人力資源和生產規模的擴大
晶片器官晶片市場：市場機遇
- 多重器官（晶片人體）整合
- 個人化醫療與新應用拓展

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

美國
歐洲
日本
中國

第6章：波特五力分析

第7章：器官晶片市場：評估

依產品類型
- 產品
- 服務
依器官類型
- Liver-on-a-Chip
- Lung-on-a-Chip
- Heart-on-a-Chip
- Kidney-on-a-Chip
- 其他
透過使用
- 藥物發現與開發
- 藥物毒性測試
- 疾病建模
- 個人化醫療
- 藥物動力學和動態研究
最終用戶
- 製藥和生物技術公司
- 學術研究機構
- 受託研究機構
按地區
- 北美洲
- 歐洲
- 亞太地區
- 世界其他地區

第8章：器官晶片市場：競爭格局

市場集中度與結構
競爭定位與市場佔有率分析（加值服務）

第9章：器官晶片市場：新創企業資金籌措與投資趨勢

第10章器官器官晶片市場：公司概況與產品概況

Emulate, Inc.
MIMETAS
CN Bio
TissUse GmbH
InSphero AG
Kirkstall Ltd.
Nortis Inc.
Hesperos, Inc.
AxoSim
Altis Biosystems

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章免責聲明與聯絡方式

簡介目錄圖表

Product Code: DIMDCL0963

Organ-on-Chip Market Summary

Overview:

The Organ-on-Chip market is estimated at USD 0.52 billion in 2025 and is projected to reach USD 3.10 billion by 2034. Growth is anchored in the accelerating shift away from animal testing toward human-relevant microphysiological systems, expanding pharmaceutical adoption of predictive preclinical models, and supportive regulatory momentum from the FDA and other global agencies.
The global Organ-on-Chip market is growing at a CAGR of 22.0% during the forecast period from 2026 to 2034.
By product type, the products segment (devices and consumables & accessories) dominated the Organ-on-Chip market with a 64% share in 2025.
By organ type, the liver-on-a-chip segment dominated the Organ-on-Chip market with a 29% share in 2025.
By application, the drug discovery & development segment dominated the Organ-on-Chip market with a 41% share in 2025.
By end-users, the pharmaceutical & biotechnology companies segment dominated the Organ-on-Chip market with a 57% share in 2025.
North America dominated the global Organ-on-Chip market revenue with a 48% share in 2025, representing the highest regional market share globally.

An organ-on-chip (OoC) is a microengineered, microfluidic cell-culture device lined with living human cells that reproduces the structure, mechanical forces, and physiological responses of a specific human organ or organ interface on a miniature platform. Because these systems combine human-derived cells, biomaterials, and precisely controlled fluid flow, they generate more human-relevant, predictive data on drug efficacy, toxicity, and disease mechanisms than conventional two-dimensional cell culture or animal models, while supporting the global movement to reduce, refine, and replace animal testing. The market is organized by product type across products, comprising devices and consumables & accessories, and services; by organ type, including liver, lung, heart, kidney, and other organs such as skin, gut, and multi-organ (body-on-a-chip) systems; by application across drug discovery & development, drug toxicity testing, disease modeling, personalized medicine, pharmacokinetic/pharmacodynamic studies, and others; and by end-users, led by pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and others. Driven by accelerating regulatory endorsement of new approach methodologies (NAMs), rising pharmaceutical outsourcing of predictive toxicology, and deepening big-pharma partnerships, organ-on-chip platforms have moved from academic proof-of-concept toward becoming an established pillar of the modern human-relevant drug development toolkit.

Organ-on-Chip Market Key Growth Drivers

The FDA's April 2025 roadmap to phase out animal-testing requirements for preclinical safety and toxicity studies over the next three to five years is directly accelerating pharmaceutical adoption of organ-chip and other new approach methodologies (NAMs).
The NIH's mid-2025 policy requiring new funding announcements involving animal models to incorporate human-focused approaches, including organ chips, is expanding research-grade demand across academic and translational programs.
Emulate's Liver-Chip becoming the first organ-chip accepted into the FDA's Innovative Science and Technology Approaches for New Drugs (ISTAND) program is establishing a regulatory qualification pathway that is expected to accelerate broader agency acceptance of chip-based data.
Deepening strategic partnerships between organ-chip developers and large pharmaceutical companies, including Emulate's collaborations with Roche, AstraZeneca, Merck, and Janssen, and Hesperos' partnerships with Bayer Consumer Health and Psilera, are embedding chip-based testing into sponsor drug-safety workflows.
The rising global burden of chronic and complex diseases, including cardiovascular disorders, cancer, and neurodegenerative conditions, is expanding demand for physiologically relevant disease-modeling and toxicity-testing platforms.
Growing regulatory momentum outside the United States, including the United Kingdom's November 2025 moves to reduce reliance on animal testing, is broadening the addressable geography for organ-chip adoption.
Formation of industry coalitions such as the Industry Alliance for Microphysiological Systems (IAMPS), launched in February 2025 by MIMETAS, TissUse, InSphero, and other founding members, is standardizing validation practices and strengthening buyer confidence in the technology.
The convergence of regulatory endorsement, big-pharma partnership activity, disease burden, and cross-industry standardization is expected to sustain strong double-digit growth in the market through 2034.

Key Companies in Organ-on-Chip Market

The competitive landscape is led by the following active manufacturers:

Emulate, Inc.
MIMETAS
CN Bio
TissUse GmbH
InSphero AG
Kirkstall Ltd.
Nortis Inc.
Hesperos, Inc.
AxoSim
Altis Biosystems

Factors Contributing to the Growth of the Organ-on-Chip Market

Market Drivers

Accelerating Regulatory Endorsement of Non-Animal Testing Methods

The single most powerful driver of the Organ-on-Chip market is the accelerating regulatory shift away from animal testing toward validated new approach methodologies. In April 2025, the U.S. FDA announced a strategic roadmap to make animal testing the exception, rather than the norm, for preclinical safety and toxicity studies within three to five years, positioning organ-chip technology alongside organoids, computational modeling, and artificial intelligence as core replacement tools. The NIH reinforced this direction the same year by requiring new funding announcements involving animal models to incorporate human-focused approaches. Emulate's Liver-Chip has become the first organ-chip technology accepted into the FDA's ISTAND program, a qualification pathway for tools that fall outside existing frameworks, giving sponsors a clearer route to regulatory-grade use of chip-derived data. As these frameworks mature and expand to additional organ systems and disease contexts, pharmaceutical sponsors are expected to steadily increase organ-chip adoption across the drug development pipeline, anchoring market growth through 2034.

Deepening Big-Pharma and Strategic Partnerships

A structural wave of partnership activity between organ-chip developers and large pharmaceutical companies is embedding the technology into mainstream drug-safety and efficacy workflows. Emulate has established strategic collaborations with Roche, AstraZeneca, Merck, and Janssen spanning safety prediction, disease mechanisms, and patient-derived cell models, while Hesperos has partnered with Bayer Consumer Health on a human-on-a-chip model of stress-induced cognitive dysfunction and with Psilera to advance preclinical modeling of a neuropsychiatric drug candidate for frontotemporal dementia. CN Bio and Altis Biosystems have jointly developed a next-generation human gut/liver in vitro model to support advanced ADME studies. These sponsor-embedded collaborations validate organ-chip technology at the point of pharmaceutical decision-making, generate recurring revenue for platform providers, and create durable reference programs that accelerate adoption by additional sponsors across the forecast period.

Market Restraints

Despite strong momentum, the Organ-on-Chip market faces material constraints. The high cost of organ-chip devices, instrumentation, and consumables, combined with the specialized microfluidics engineering and cell-biology expertise required to operate them, limits adoption among smaller academic laboratories and budget-constrained research institutes. The absence of fully harmonized regulatory qualification pathways beyond early programs such as the FDA's ISTAND initiative creates uncertainty for sponsors seeking to rely on chip-derived data for regulatory submissions, slowing broader adoption. Technical challenges around inter-laboratory reproducibility, standardization of cell sourcing, and long-term validation against clinical outcomes remain active areas of development. Competition from alternative new approach methodologies, including organoids, computational and AI-driven modeling, and advanced 2D/3D co-culture systems, creates a fragmented and rapidly evolving competitive landscape. A shortage of professionals trained across microfluidics, tissue engineering, and translational biology constrains the pace of scale-up, while low-throughput manufacturing at many specialized providers limits the volume of chips that can be supplied to large pharmaceutical customers. Together, these cost, regulatory, technical, and workforce barriers temper the pace of growth, even as the underlying drivers of regulatory endorsement, disease burden, and pharmaceutical outsourcing remain firmly intact.

Organ-on-Chip Market Segment Analysis

The organ-on-chip market by product type (products {devices and consumables & accessories} and services), organ type (liver-on-a-chip, lung-on-a-chip, heart-on-a-chip, kidney-on-a-chip, and others), application (drug discovery & development, drug toxicity testing, disease modeling, personalized medicine, pharmacokinetic/pharmacodynamic studies, and others), end-users (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Products (Devices and Consumables & Accessories).

The products segment accounted for 64% of the Organ-on-Chip market in 2025. Products are the leading category because organ-chip adoption fundamentally requires recurring purchases of physical devices, microfluidic chips, and consumables such as membranes, scaffolds, and reagents to run each new experiment or screening campaign. Devices and platforms, including chip cartridges, culture plates, and supporting instrumentation such as pumps and perfusion controllers, form the durable hardware backbone that laboratories invest in first, while consumables and accessories generate steady repeat revenue tied to experimental throughput. Leading providers including Emulate, MIMETAS, and CN Bio sell modular, plug-and-play systems compatible with standard laboratory equipment, lowering the barrier for pharmaceutical and academic customers to adopt the hardware. While the services segment, spanning contract assay development, custom tissue modeling, and data interpretation, is growing quickly as sponsors seek turnkey solutions without in-house expertise, the recurring nature and higher unit economics of device and consumable sales secure the products segment's leadership across the forecast period.

By Organ Type

Dominant Subsegment: Liver-on-a-Chip.

The liver-on-a-chip segment accounted for 29% of the Organ-on-Chip market in 2025. Liver-on-a-chip is the leading organ type because hepatotoxicity remains the single most common cause of drug candidate failure and post-market withdrawal, making liver models the earliest and most extensively validated application of the technology. Emulate's Liver-Chip, the first organ-chip accepted into the FDA's ISTAND program for drug-induced liver injury evaluation, exemplifies the regulatory traction that liver models have achieved relative to other organ systems. Kirkstall's Quasi Vivo perfusion platform and CN Bio's liver-focused systems further reinforce the segment's breadth of validated commercial offerings. Lung-on-a-chip and heart-on-a-chip are expanding quickly, driven by respiratory disease research and cardiotoxicity screening, respectively, and kidney-on-a-chip is gaining traction in nephrotoxicity testing led by providers such as Nortis. Nonetheless, the depth of validation data, regulatory precedent, and breadth of commercial liver-chip offerings secure the segment's leadership across the forecast period.

Organ-on-Chip Market Region Analysis

Dominant Region: North America

North America accounted for 48% of the global Organ-on-Chip market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a dense concentration of organ-chip technology developers, including Emulate, Nortis, Hesperos, AxoSim, and Altis Biosystems, a mature pharmaceutical R&D ecosystem, and clear regulatory tailwinds from the FDA's 2025 roadmap to reduce animal testing and the NIH's human-focused research funding requirements. The United States hosts the largest concentration of organ-chip commercial and academic research activity, anchored by Emulate's ISTAND-accepted Liver-Chip program and its strategic partnerships with major pharmaceutical companies. Strong venture and grant funding, exemplified by recent financing rounds at Altis Biosystems and AxoSim, continues to support platform development and commercialization. Robust research infrastructure, regulatory clarity, and proximity to leading pharmaceutical sponsors anchor the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Organ-on-Chip market. The region's elevated CAGR is driven by rapidly expanding biopharmaceutical R&D investment, government-backed life-sciences initiatives, and a growing base of contract research organizations across China, Japan, India, South Korea, and Australia. China is scaling domestic microphysiological systems research and manufacturing capacity, Japan is integrating organ-chip platforms into its regenerative-medicine and drug-safety ecosystem, and India is emerging as a lower-cost hub for chip-based contract research services. Growing academic-industry collaboration, rising chronic disease burden, and expanding local biotechnology funding are accelerating adoption, while regional providers increasingly partner with established Western developers to access validated platforms. The combination of R&D investment, cost-competitive services capacity, and expanding pharmaceutical outsourcing positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 48% of the global Organ-on-Chip market revenue in 2025. The United States dominates on the strength of its concentration of organ-chip developers, mature pharmaceutical R&D base, and clear regulatory momentum from the FDA and NIH, while strong venture funding and deepening big-pharma partnerships reinforce its leadership.

Europe

Europe is a large and technically advanced regional market, supported by pioneering developers including MIMETAS, TissUse, InSphero, and Kirkstall, a strong academic microfluidics research base, and growing regulatory alignment with the 3Rs principle. The February 2025 launch of the Industry Alliance for Microphysiological Systems, founded predominantly by European companies, and the United Kingdom's November 2025 regulatory moves to reduce animal testing reinforce the region's role as a hub for organ-chip innovation and standardization across Germany, the United Kingdom, France, Italy, and Spain.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by expanding biopharmaceutical R&D investment, government life-sciences initiatives, and a growing contract research organization base across China, Japan, India, South Korea, and Australia. Rising local funding and academic-industry collaboration are accelerating regional organ-chip adoption and clinical-translation activity.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding biomedical research infrastructure, growing interest in ethical and cost-effective alternatives to animal testing, and international academic partnerships are gradually broadening access, while local capacity for organ-chip research remains nascent relative to North America, Europe, and Asia-Pacific.

Organ-on-Chip Market Competitive Landscape

The Organ-on-Chip market is classified as Fragmented. A group of well-funded, first-mover platform developers, including Emulate, MIMETAS, CN Bio, and TissUse, anchors the top tier through broad organ-model portfolios, regulatory traction, and big-pharma partnerships, while specialized providers such as InSphero, Kirkstall, Nortis, Hesperos, AxoSim, and Altis Biosystems compete through organ-specific expertise, academic collaborations, and niche application focus, sustaining intense innovation-driven competition across the vendor landscape.

The competitive landscape can be evaluated across the following dimensions:

Market concentration: Fragmented, with a handful of broad-portfolio platform leaders and a large field of organ-specific specialized providers.
Leading players: Emulate, MIMETAS, CN Bio, and TissUse anchor the top tier through multi-organ portfolios and regulatory and pharma-partnership traction.
Regulatory positioning: Emulate's Liver-Chip acceptance into the FDA's ISTAND program is a decisive competitive advantage, establishing a precedent that other developers are working to replicate for additional organ systems.
Product portfolio strength: Top players offer modular, plug-and-play organ-chip systems spanning liver, lung, heart, kidney, gut, and neural models, compatible with standard laboratory equipment.
Strategic partnerships: Tie-ups with pharmaceutical sponsors, such as Emulate's collaborations with Roche, AstraZeneca, Merck, and Janssen, and Hesperos' partnerships with Bayer Consumer Health and Psilera, extend commercial reach and validate technology.
Industry collaboration: Founding participation in the Industry Alliance for Microphysiological Systems (IAMPS) by MIMETAS, TissUse, InSphero, and others is shaping shared validation standards across the sector.
Funding activity: Active venture and grant funding, including recent rounds at Altis Biosystems and AxoSim, continues to support platform development and commercialization among specialized providers.
Technology focus: Multi-organ (body-on-a-chip) integration, patient-derived and iPSC-based cell sourcing, and automated, high-throughput chip manufacturing are key competitive differentiators.
Innovation focus: Regulatory-grade validation studies, novel application domains such as space biomedicine, and standardized cross-laboratory protocols define the next phase of competition.

Organ-on-Chip Market Recent Developmental Activities

In April 2026, Emulate, Inc. launched its organ-chip technology, containing astronaut-derived cells, aboard NASA's Artemis II lunar mission as part of the AVATAR investigation studying the effects of deep-space radiation and microgravity on human tissue.

In April 2025, Emulate, Inc. welcomed the FDA's newly announced roadmap to reduce reliance on animal testing and applauded the agency's embrace of organ-chip technologies as validated new approach methodologies.

Organ-on-Chip Market Segmentation

Organ-on-Chip Market by Product Type

Products
Devices
Consumables & Accessories
Services

Organ-on-Chip Market by Organ Type

Liver-on-a-Chip
Lung-on-a-Chip
Heart-on-a-Chip
Kidney-on-a-Chip
Others

Organ-on-Chip Market by Application

Drug Discovery & Development
Drug Toxicity Testing
Disease Modeling
Personalized Medicine
Pharmacokinetic/Pharmacodynamic Studies
Others

Organ-on-Chip Market by End-Users

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
Others

Organ-on-Chip Market by Geography

North America Organ-on-Chip Market
United States Organ-on-Chip Market Size in USD million (2023-2034)
Canada Organ-on-Chip Market Size in USD million (2023-2034)
Mexico Organ-on-Chip Market Size in USD million (2023-2034)
Europe Organ-on-Chip Market
Germany Organ-on-Chip Market Size in USD million (2023-2034)
United Kingdom Organ-on-Chip Market Size in USD million (2023-2034)
France Organ-on-Chip Market Size in USD million (2023-2034)
Italy Organ-on-Chip Market Size in USD million (2023-2034)
Spain Organ-on-Chip Market Size in USD million (2023-2034)
Rest of Europe Organ-on-Chip Market Size in USD million (2023-2034)
Asia-Pacific Organ-on-Chip Market
China Organ-on-Chip Market Size in USD million (2023-2034)
Japan Organ-on-Chip Market Size in USD million (2023-2034)
India Organ-on-Chip Market Size in USD million (2023-2034)
Australia Organ-on-Chip Market Size in USD million (2023-2034)
South Korea Organ-on-Chip Market Size in USD million (2023-2034)
Rest of Asia-Pacific Organ-on-Chip Market Size in USD million (2023-2034)
Rest of the World (RoW) Organ-on-Chip Market
Middle East Organ-on-Chip Market Size in USD million (2023-2034)
Africa Organ-on-Chip Market Size in USD million (2023-2034)
South America Organ-on-Chip Market Size in USD million (2023-2034)

Key Takeaways from the Organ-on-Chip Market Report Study

Market size analysis for the current organ-on-chip market size (2025), and market forecast for 9 years (2026 to 2034).
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
Key companies dominating the global organ-on-chip market.
Various opportunities available for competitors in the organ-on-chip market space.
What are the top-performing segments in 2025? How will these segments perform in 2034?
Which are the top-performing regions and countries in the current organ-on-chip market scenario?
Which are the regions and countries where companies should concentrate their opportunities for organ-on-chip market growth in the future?

Target audience who can benefit from this organ-on-chip market report study

Organ-on-Chip product providers
Research organizations and consulting companies
Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in organ-on-chip
Various end-users who want to know more about the organ-on-chip market and the latest technological developments in the organ-on-chip market.

Frequently Asked Questions:

Q1. What is the growth rate of the organ-on-chip market?

The organ-on-chip market is projected to expand at a CAGR of 22.0% during the forecast period from 2026-2034.

Q2. What is the market size of the organ-on-chip market?

The organ-on-chip market is estimated at USD 0.52 billion in 2025 and is projected to reach USD 3.10 billion by 2034.

Q3. Which region dominates the organ-on-chip market?

North America dominated the Organ-on-Chip market with a 48% share of global revenue in 2025, supported by a dense concentration of organ-chip technology developers, a mature pharmaceutical R&D ecosystem, and clear regulatory tailwinds from the FDA and NIH. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the organ-on-chip market?

The principal drivers are the FDA's April 2025 roadmap to phase out animal testing over three to five years; the NIH's human-focused research funding requirements; deepening strategic partnerships between organ-chip developers and major pharmaceutical companies; the rising global burden of chronic and complex diseases; growing international regulatory alignment, including in the United Kingdom; and industry standardization efforts such as the February 2025 launch of the Industry Alliance for Microphysiological Systems.

Q5. Who are the major players in the organ-on-chip market?

The major players include Emulate, Inc., MIMETAS, CN Bio, TissUse GmbH, InSphero AG, Kirkstall Ltd., Nortis Inc., Hesperos, Inc., AxoSim, and Altis Biosystems, among other active providers profiled in the Competitive Landscape section. Emulate, MIMETAS, CN Bio, and TissUse lead through broad organ-model portfolios and regulatory and pharma-partnership traction.

1. Organ-on-Chip Market Report Introduction

1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions

2. Organ-on-Chip Market Executive Summary

2.1 Market at a Glance

3. Organ-on-Chip Market Key Factors Analysis

3.1 Organ-on-Chip Market Drivers
- 3.1.1 Regulatory Endorsement of Non-Animal Testing Methods
- 3.1.2 Deepening Big-Pharma and Strategic Partnerships
- 3.1.3 Rising Global Burden of Chronic and Complex Diseases
- 3.1.4 Expanding Pharmaceutical Outsourcing of Predictive Toxicology
3.2 Organ-on-Chip Market Restraints and Challenges
- 3.2.1 High Cost and Specialized Expertise Requirements
- 3.2.2 Regulatory Qualification and Standardization Gaps
- 3.2.3 Reproducibility, Workforce, and Manufacturing Scale-Up
3.3 Organ-on-Chip Market Opportunities
- 3.3.1 Multi-Organ (Body-on-a-Chip) Integration
- 3.3.2 Personalized Medicine and Novel Application Expansion

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

5.1 United States
5.2 Europe
5.3 Japan
5.4 China

6. Organ-on-Chip Market Porter's Five Forces Analysis

6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. Organ-on-Chip Market Assessment

7.1 By Product Type
- 7.1.1 Products
  - 7.1.1.1 Devices
  - 7.1.1.2 Consumables & Accessories
- 7.1.2 Services
7.2 By Organ Type
- 7.2.1 Liver-on-a-Chip
- 7.2.2 Lung-on-a-Chip
- 7.2.3 Heart-on-a-Chip
- 7.2.4 Kidney-on-a-Chip
- 7.2.5 Others
7.3 By Application
- 7.3.1 Drug Discovery & Development
- 7.3.2 Drug Toxicity Testing
- 7.3.3 Disease Modeling
- 7.3.4 Personalized Medicine
- 7.3.5 Pharmacokinetic/Pharmacodynamic Studies
- 7.3.6 Others
7.4 By End-Users
- 7.4.1 Pharmaceutical & Biotechnology Companies
- 7.4.2 Academic & Research Institutes
- 7.4.3 Contract Research Organizations
- 7.4.4 Others
7.5 By Geography
- 7.5.1 North America
  - 7.5.1.1 United States Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.1.2 Canada Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.1.3 Mexico Organ-on-Chip Market Size in USD million (2023-2034)
- 7.5.2 Europe
  - 7.5.2.1 Germany Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.2.2 United Kingdom Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.2.3 France Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.2.4 Italy Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.2.5 Spain Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.2.6 Rest of Europe Organ-on-Chip Market Size in USD million (2023-2034)
- 7.5.3 Asia-Pacific
  - 7.5.3.1 China Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.3.2 Japan Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.3.3 India Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.3.4 Australia Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.3.5 South Korea Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.3.6 Rest of Asia-Pacific Organ-on-Chip Market Size in USD million (2023-2034)
- 7.5.4 Rest of World
  - 7.5.4.1 Middle East Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.4.2 Africa Organ-on-Chip Market Size in USD million (2023-2034)
  - 7.5.4.3 South America Organ-on-Chip Market Size in USD million (2023-2034)

8. Organ-on-Chip Market Competitive Landscape

8.1 Market Concentration and Structure
8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Organ-on-Chip Market Startup Funding and Investment Trends

10. Organ-on-Chip Market Company and Product Profiles

10.1 Emulate, Inc.
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
10.2 MIMETAS
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
10.3 CN Bio
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
10.4 TissUse GmbH
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
10.5 InSphero AG
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
10.6 Kirkstall Ltd.
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
10.7 Nortis Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
10.8 Hesperos, Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
10.9 AxoSim
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy

10. Altis Biosystems

10.10.1 Company Overview
10.10.2 Company Snapshot
10.10.3 Financial Overview
10.10.4 Product Portfolio
10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.